Martin Madaus

Martin D.
Madaus is President, Chief Executive Officer & Director at Azenta, Inc. since 2026.
He is Chairman of Repligen Corp.
starting in 2026.
He serves as Executive Chairman at Emulate, Inc. since 2020.
He holds director positions at Candela Corp., Massachusetts High Technology Council, Inc., Unchained Labs LLC since 2021, Ultivue, Inc., Candela Medical, Inc. since 2018, Syntis Bio, Inc., Haemonetics Corp.
starting in 2026, and is Senior Operating Executive at The Carlyle Group Inc. since 2019.
Former roles include Chairman, President & Chief Executive Officer at EMD Millipore Corp.
in 2010; Chairman & Chief Executive Officer at Ortho-Clinical Diagnostics, Inc. from 2014 to 2019; President & Chief Executive Officer at Roche Diagnostics Corp.
from 2000 to 2004; Chairman, President & Chief Executive Officer at Millipore SA from 2005 to 2010; Independent Director at Mettler-Toledo International, Inc. from 2011 to 2015; Independent Director at Covidien Unlimited Co. from 2011 to 2014; Independent Director at Standard BioTools, Inc. from 2022 to 2024; Independent Director at Hologic, Inc. from 2024 to 2026; Director at Quanterix Corp.
from 2010 to 2025; Chief Operations Officer at Sherlock Biosciences, Inc. from 2020 to 2021; Vice President-Business Development at Roche Molecular Systems, Inc.; Director at Pharmaceutical Product Development LLC, New England Healthcare Institute, Massachusetts Technology Collaborative, Predictive Biosciences, Inc., Young Men's Christian Association of Greater Boston, Inc., and Analytical Life Science & Diagnostics Association.
Education includes doctorates from Ludwig-Maximilians-Universität München in 1985 and The University of Veterinary Medicine Hanover.